Major Terry C, Dhamija Shantanu, Black Nicole, Liachenko Serguei, Morenko Brandy, Sobocinski Gregg, Okerberg Carlin, Tinholt Paula, Madore Steven, Kowala Mark C
Cardiovascular and Atherosclerosis Biology, Pfizer Global Research & Development, Pfizer, Inc., Groton, Connecticut, USA.
J Pharmacol Exp Ther. 2008 Jun;325(3):723-31. doi: 10.1124/jpet.107.133892. Epub 2008 Mar 7.
Among the L-type calcium channel blockers (CCBs), particularly dihydropyridines like nifedipine [1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester], a common adverse effect is vasodilatory edema. Newer CCBs, such as the T- and L-type CCB, mibefradil [(1S,2S)-2-[2[[3-(2-benzimidazolylpropyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride hydrate], demonstrate antihypertensive efficacy similar to that of their predecessors but seem to have a reduced propensity to cause edema. Using a magnetic resonance imaging (MRI) T(2) mapping technique, we investigated the ability of mibefradil to reduce extracellular water accumulation caused by the L-type CCB, nifedipine, in the hindleg skeletal muscle of the spontaneously hypertensive rat. Mibefradil (10 mg/kg i.v.) and nifedipine (1 mg/kg i.v.) lowered mean arterial blood pressure by 97 +/- 5 and 77 +/- 4 mm Hg, respectively. MRI edema index (expressed as percentage increase of integral T(2) over predrug control) was significantly higher with nifedipine (2606 +/- 86%; p < 0.05) than with mibefradil (981 +/- 171%) measured 30 to 60 min after the start of drug infusion. The hindleg edema caused by nifedipine was dose dependently decreased by coadministration of mibefradil (0, 0.3, or 3 mg/kg). The hindleg edema formation was not due to albumin leakage into the interstitial space based on immunostaining. However, a 4.2-fold increase in the arterial L-/T-type CC mRNA expression ratio was observed compared with the venous L/T ratio as shown by quantitative reverse transcription polymerase chain reaction. These results demonstrate the novel utility of MRI to measure extravascular water after acute exposure to CCBs and indicate that T-type CCB activity may reduce L-type CCB-induced vasodilatory edema in the skeletal muscle vasculature, possibly by a differential effect on arteriole and venule dilatation.
在L型钙通道阻滞剂(CCB)中,尤其是二氢吡啶类药物,如硝苯地平[1,4 - 二氢 - 2,6 - 二甲基 - 4 - (2 - 硝基苯基)-3,5 - 吡啶二甲酸二甲酯],常见的不良反应是血管舒张性水肿。新型CCB,如T型和L型CCB米贝拉地尔[(1S,2S)-2 - [2[[3 - (2 - 苯并咪唑基丙基]甲基氨基]乙基]-6 - 氟 - 1,2,3,4 - 四氢 - 1 - 异丙基 - 2 - 萘基甲氧基乙酸二盐酸盐水合物],显示出与前代药物相似的降压效果,但引起水肿的倾向似乎降低。我们使用磁共振成像(MRI)T(2)映射技术,研究了米贝拉地尔减少自发性高血压大鼠后肢骨骼肌中由L型CCB硝苯地平引起的细胞外积水的能力。米贝拉地尔(静脉注射10 mg/kg)和硝苯地平(静脉注射1 mg/kg)分别使平均动脉血压降低97±5和77±4 mmHg。在药物输注开始后30至60分钟测量,硝苯地平组的MRI水肿指数(表示为积分T(2)相对于给药前对照的百分比增加)显著高于米贝拉地尔组(分别为2606±86%;p < 0.05和981±171%)。联合给予米贝拉地尔(0、0.3或3 mg/kg)可剂量依赖性地减轻硝苯地平引起的后肢水肿。基于免疫染色结果,后肢水肿的形成并非由于白蛋白漏入间质间隙。然而,定量逆转录聚合酶链反应显示,与静脉L/T比值相比,动脉L型/T型CC mRNA表达比值增加了4.2倍。这些结果证明了MRI在急性暴露于CCB后测量血管外积水的新用途,并表明T型CCB活性可能通过对小动脉和小静脉扩张的不同作用来减少L型CCB诱导的骨骼肌血管舒张性水肿。